Essays on the Availability, Legality, and Reasons for Using Hemp-Derived Cannabinoid Products
Skip to main content
eScholarship
Open Access Publications from the University of California

UC San Diego

UC San Diego Electronic Theses and Dissertations bannerUC San Diego

Essays on the Availability, Legality, and Reasons for Using Hemp-Derived Cannabinoid Products

No data is associated with this publication.
Abstract

Background: The passage of the 2018 United States (US) Farm Bill, which separated “hemp” from the definition of “marijuana”, resulted in the growth of a market for hemp-derived cannabinoid products, such as cannabidiol (CBD) and delta-8-THC. Hemp-derived cannabinoid products are those derived from Cannabis Sativa L. that contain less than 0.3% delta-9-THC, which is the main psychoactive compound in cannabis. Although the new and unregulated marketplace of hemp-derived cannabinoid products poses several health risks to consumers, there is a scarcity of data to answer basic epidemiological questions about their use. Methods: This dissertation is comprised of three chapters. Chapters 2 and 3 utilized data from a nationally representative sample of US adults recruited from the Ipsos KnowledgePanel to describe the characteristics and motivations of hemp-derived cannabinoid product use (Chapter 2) and estimate the association between lifetime use of delta-8-THC and state cannabis use laws and regulations on delta-8-THC, independently and in combination (Chapter 3). Chapter 4 used data from a sample of e-commerce tobacco retailers serving San Diego County to examine the association between hemp-derived cannabinoid product availability and website visits and assess compliance with state hemp regulations. Results: In Chapter 2 we found that there is heterogeneity among US adults who use hemp-derived cannabinoid products in terms of sociodemographic characteristics, medical versus recreational reasons for use, and specific medical reasons for use. Most adults used CBD for medical reasons and delta-8-THC for recreation. Anxiety and pain were the most frequently reported medical conditions for using hemp-derived cannabinoid products. In Chapter 3 we showed that medical and recreational cannabis use laws and delta-8-THC restrictions were associated with a lower probability of delta-8-THC use. Among states with recreational cannabis use laws, having delta-8-THC restrictions decreased the probability of delta-8-THC use. In Chapter 4 we found that tobacco retailers that offered hemp-derived cannabinoid products received more website visits, and a sizeable number of retailers were out of compliance with state hemp regulations. Conclusion: These data suggest that hemp-derived cannabinoid products are widely available, used to relieve medical symptoms, and used as a legal substitute to cannabis. Evidence-based education, federal regulations, and better enforcement of existing state laws for hemp-derived cannabinoid products are crucial for ensuring consumer safety and limiting youth access, both essential for protecting public health.

Main Content

This item is under embargo until September 17, 2026.